SEZL Jumps 15.6% on EPS Revision, NVAX, RZLT, SNAP Gain 12%+
Sezzle (SEZL) led today's EPS-revision gainers, surging 15.6% since being detected on October 6 as analysts lifted its next-year EPS growth estimate to 27.3%. Novavax (NVAX) climbed 12.8% after a 20 percentage-point upward revision in its EPS growth estimate to 97.3%, while Rezolute (RZLT) and Snap (SNAP) each gained over 12% on similar estimate increases and confirming news catalysts.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SEZL | Financial | 2026-10-06 | N/A | +15.6% |
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +12.8% |
| RZLT | Healthcare | 2026-10-06 | +1.7pp | +12.7% |
| SNAP | Communication Services | 2026-10-07 | +12.0pp | +12.4% |
| IOVA | Healthcare | 2026-10-08 | +4.4pp | +9.4% |
Why did SEZL stock jump in October 2026?
SEZL jumped 15.6% (from $112.84 to $130.48) after analysts raised its next-year EPS growth estimate to 27.3% on October 6.
The stock is the best-performing consumer finance name of 2026, up over 77% year-to-date, and a TD Cowen Q3 preview and upcoming conference schedule reinforced the bullish narrative. The screener caught the revision early, and the market confirmed it with steady buying through the week.
SEZL EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: SEZL
Why did SEZL stock jump today?
SEZL jumped 15.6% from $112.84 to $130.48 after its next-year EPS growth estimate was revised to 27.3%. The move was reinforced by a TD Cowen Q3 preview and Sezzle's upcoming investor conference schedule.
Is SEZL a buy after the rally?
The EPS growth estimate of 27.3% supports a bullish case, but shares are already up over 77% year-to-date. Investors should weigh the strong estimate against the extended valuation.
What caused SEZL's surge this week?
The surge was caused by an upward EPS estimate revision on October 6, combined with positive sector attention from TD Cowen's Q3 preview. No single news event drove it, but the revision triggered the screener and subsequent buying.
Why did NVAX stock jump in October 2026?
NVAX jumped 12.8% (from $11.22 to $12.66) after its next-year EPS growth estimate was revised from 77.3% to 97.3% on October 7.
No specific earnings news was found, but the sharp upward revision in expected profitability likely reflected improving vaccine demand or cost-cut optimism. The screener flagged the estimate change, and the price followed with a steady climb.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock jump on October 7?
NVAX jumped 12.8% from $11.22 to $12.66 after its next-year EPS growth estimate was revised upward from 77.3% to 97.3% on October 7. No single news catalyst was found, but the estimate change signaled improving fundamentals.
What is NVAX's EPS growth estimate?
NVAX's next-year EPS growth estimate is 97.3%, up from 77.3% before the revision. This 20 percentage-point increase was the key driver behind the stock's recent gain.
Is NVAX a buy after its recent rally?
The upward EPS revision to 97.3% suggests analysts see sharply improving earnings, but the lack of a clear news catalyst means the rally could be fragile. Investors should watch for upcoming earnings or pipeline updates.
Why did RZLT stock jump in October 2026?
RZLT jumped 12.7% (from $4.32 to $4.87) after its next-year EPS growth estimate was revised from 25.6% to 27.3% on October 6.
The gain was reinforced by positive FDA news on October 5, when the agency recommended a pre-BLA meeting for Ersodetug despite a Phase 3 miss. The screener caught the estimate revision early, and the FDA's openness to a filing pathway lifted sentiment further.
RZLT EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: RZLT
Why did RZLT stock jump this week?
RZLT jumped 12.7% from $4.32 to $4.87 after its next-year EPS growth estimate was revised up to 27.3% on October 6. The move was amplified by FDA's recommendation of a pre-BLA meeting for Ersodetug on October 5.
What caused RZLT's surge after the FDA update?
The FDA recommended a Type B pre-BLA meeting for Ersodetug, indicating a potential path to filing despite a Phase 3 miss. This positive regulatory signal, combined with an EPS estimate revision, drove the surge.
What is RZLT's EPS growth estimate?
RZLT's next-year EPS growth estimate is 27.3%, revised upward from 25.6%. The increase was modest but came alongside positive FDA news, fueling a double-digit gain.
Why did SNAP stock jump in October 2026?
SNAP jumped 12.4% (from $5.81 to $6.53) after its next-year EPS growth estimate was revised from 399.7% to 411.7% on October 7.
The rally was supported by activist investor Blue Duck Capital urging the board to raise external capital for Specs, which could unlock a sum-of-parts valuation of $12–14 per share. The screener flagged the estimate revision, and the market responded to the combination of earnings optimism and activist pressure.
SNAP EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: SNAP
Why did SNAP stock jump in October 2026?
SNAP jumped 12.4% from $5.81 to $6.53 after its next-year EPS growth estimate was revised from 399.7% to 411.7% on October 7. The move was reinforced by an activist letter urging a Specs capital raise.
What is SNAP's EPS growth estimate?
SNAP's next-year EPS growth estimate is 411.7%, up from 399.7% before the revision. This extremely high figure reflects expected earnings recovery from a low base.
Is SNAP a buy after the rally?
The upward EPS revision and activist push for a Specs spin-off could unlock value, but the stock remains speculative. Investors should watch Q3 results and any board response to Blue Duck's proposal.
Why did IOVA stock jump in October 2026?
IOVA jumped 9.4% (from $13.31 to $14.56) after its next-year EPS growth estimate was revised from 53.9% to 58.2% on October 8.
No specific earnings news was found, but the revision likely reflected growing confidence in Iovance's tumor-infiltrating lymphocyte therapies. The screener detected the estimate change, and the stock rallied as investors anticipated continued adoption of its lead product.
IOVA EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: IOVA
Why did IOVA stock jump on October 8?
IOVA jumped 9.4% from $13.31 to $14.56 after its next-year EPS growth estimate was revised from 53.9% to 58.2% on October 8. No single news catalyst was found, but the estimate change signaled improving prospects.
What is IOVA's EPS growth estimate?
IOVA's next-year EPS growth estimate is 58.2%, up from 53.9% before the revision. This 4.4 percentage-point increase supported the stock's recent gain.
Is IOVA a buy after the rally?
The upward EPS revision suggests analysts see accelerating earnings, but the lack of a clear catalyst makes the move less certain. Investors should monitor upcoming clinical and commercial updates.
Today's double-digit gainers were driven by upward EPS estimate revisions, signaling that analysts are growing more confident in earnings growth despite macro uncertainty. The market rewarded these revisions, especially where reinforced by positive news, suggesting a favorable environment for stocks with improving profitability outlooks.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →